Geneoscopy, a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the closing of a Series C funding round raising $105 million. Bio-Rad Laboratories (NYSE: BIO and BIO.B) led the financing and was joined by Petrichor, Labcorp (NYSE: LH), Morningside Ventures, Lightchain Capital, NT Investments, Granger Management and Mercy Health, Tri Locum Partners, and others.